The hair itself, slicked and finished, at the head of a Take argued from the scalp ranking: that Card's own hero, standing over an argument about the skin underneath it. The frame shows a wearer, not a bottle: the photo bank holds no scalp product photography, a gap the ranking names on its own page and the honesty section below admits in full.

Checked and updated October 2026

The thesis: the law prints the number

Begin with the shelf’s most precise document, because its precision is the argument in miniature. The Brickell Relieving Anti-Dandruff Shampoo prints its salicylic acid at 1.80%: two decimal places, a figure with the air of a laboratory notebook about it, standing on a bottle sold inside a three-product system by a boutique house whose other shelves in this run have repeatedly failed this desk’s documentation counts. The 1.80% is not the house’s newfound love of exactitude. It is the figure on a federal Drug Facts panel, filed on DailyMed, and it is printed to two decimals because the panel’s format is the format, the same format that prints the Nizoral’s ketoconazole at 1%, the Head & Shoulders Clinical Strength’s selenium sulfide at 1%, and the Jupiter’s zinc pyrithione at 1.0%. Four of the scalp shelf’s five dosed records are dosed in that hand, the state’s hand, and the numbers’ family resemblance is not a coincidence of formulation. It is the resemblance of four documents written to one template by one regulator, on bottles whose makers, left to their own typography, print adjectives.

The fifth dosed record is the exception the whole ranking turns on, and the Card prints it at the top. The INKEY List’s Salicylic Acid Exfoliating Scalp Treatment is a cosmetic, filed as a cosmetic, obliged to print no percentage of anything, and it prints three: salicylic acid 2%, its FluidPure complex at 2.5%, panthenol at 1%. It prints the shelf’s only pH, 4.0 to 4.5, in its maker’s FAQ. It prints a contact time, ten minutes before shampooing, one of only two printed contact times on the shelf, and it carries no Fragrance entry and no alcohol. It stands at 86, first, ahead of the Nizoral’s compelled 1% at 85 and the Jupiter’s compelled 1.0% at 83. Read the podium as a census and it is exact: the voluntary number first, the federal numbers behind it, in the order of their documents’ completeness. The shelf did not reward a marketing culture, because there is no marketing culture to reward: of the eight houses on the page, one prints a dose because it chooses to, four print because the law files their bottles as drugs, and three print nothing at all. The dose, on the scalp shelf, is a legal category with one volunteer.

The three who print nothing are the count’s other half, and their identity matters more than their number. They are not the shelf’s stragglers or its discounters. The Christophe Robin Cleansing Purifying Scrub seats its sea salt first of 21, an honourable seat, and doses it nowhere, at $54.00 for 8.33 fl oz, $6.48 an ounce, the dearest ounce on the page. The Kiehl’s Amino Acid Scalp Scrub seats its sea salt first of 34, seats a salicylic acid sixteenth, undosed, and sells at $4.76 an ounce. The Briogeo Scalp Revival, sent home, seats its named charcoal fourteenth of 29, behind the cellulose that does the work, doses nothing on the record, and sells at $5.25 an ounce. These are the prestige cosmetics, the shelf’s texture and ritual end, documented to a high standard in every column except the number: full lists, printed frequencies, a tablespoon for a use dose on the Robin. What they withhold is the one figure their category does not compel, and they withhold it at the shelf’s highest prices. Nothing on their records is hidden. The lists are complete, the seats are countable, the claims are printed as claims. The blank is specific, and it is exactly the size and shape of a percentage.

The proof that the blank is the category’s, and not the houses’ incapacity, stands inside one of the three catalogues, and it is the cleanest document this column has been handed since the hair oil shelf’s two price tags. The house that sells the undosed Briogeo scrub also sells, in the same Scalp Revival line, a shampoo called MegaStrength+ that prints salicylic acid at 3% on a federal Drug Facts panel. Same house, same line, same shelf of the same bathroom: on the bottle the law files as a drug, a dose, in print, to a whole number with a panel around it; on the bottle the law files as a cosmetic, a charcoal at fourteenth and a percentage of nothing. The hand that withholds the number on the scrub is the hand that prints it on the shampoo, and the difference between the two bottles is not candour, capability or house style. It is a filing category. Take No. 2 opened this column’s long count of the number nobody prints, and on shelf after shelf the blank could be read as a culture, an industry habit of withholding. The scalp shelf corrects the reading: where the habit is broken, it is broken by a statute, four times, and by a choice, once, and the choice stands first in the ranking because this desk grades the document, and only one cosmetic document on the shelf is complete.

Nothing on this page is scored. Every score quoted here, every row, every price and every count is the scalp ranking’s, Verdict Card No. 100, reproduced exactly as that Card published it: The INKEY List at 86, the Nizoral at 85, the Jupiter at 83, the Head & Shoulders Clinical Strength at 81, the Christophe Robin at 75, the Kiehl’s at 73, the Brickell at 67, and the Briogeo sent home at 65. The only arithmetic of this page’s own is sorting what the record prints: which numbers stand under panels and which stand by choice, which ounces carry a dose and which carry a price instead. The brief for this issue carried the Card’s counts, and they survived the record entire; the precisions the record adds, that the cheapest dosed ounce read for the page belongs to a rested record rather than a ranked one, and that one of the four compelled doses belongs to a house this run has charged on three other shelves, are stated in the honesty section rather than absorbed, because a column about who is made to print should be exact about what it was made to read.

The record, counted

Start with completeness, because this shelf is the best documented in the grooming run and its documentation is what makes the census an argument. Full records published: eight of eight. A printed use frequency: eight of eight, every record on the page telling the buyer how often, from the Nizoral’s twice a week to the Robin’s tablespoon once a week. A Fragrance or Parfum entry: five of eight. Against that completeness, the dose column: a dosed active on five of eight, and the five sort themselves without any help from this column. Four stand on Drug Facts panels, the Nizoral, the Head & Shoulders, the Jupiter and the Brickell, their percentages filed with the federal database or printed on the panel the law prescribes. One stands on a maker’s own page by the maker’s own choice. Three stand nowhere. A shelf on which every frequency is printed and three of eight doses are not is not a shelf that fears print. It is a shelf that prints what its categories ask, each category asking for something different, and the dose is asked for only where the bottle is a drug.

The panels themselves deserve a closer read, because compulsion turns out to print unevenly, and the Card’s rows catch the unevenness. The Nizoral’s panel numbers its active and then renders its 17 inactive ingredients alphabetically on the current label, benzyl alcohol to water, so behind the compelled 1% there is no concentration order to read at all: the panel’s only numbered citizen is the active, and its honesty row stands at 24, below the winner’s 28, a compelled document graded below a voluntary one on this desk’s own basis. The Jupiter’s panel, by contrast, prints 45 inactives in concentration order and its directions print the sit, two to three minutes, the shelf’s second contact time, standing on the panel itself: on the Jupiter, even the minutes are partly compelled, a drug’s directions doing the work Take No. 15 asked every rinse-off maker to do voluntarily and almost none did. And the Brickell’s panel prints the shelf’s most precise figure, 1.80%, while its maker captures no standalone price the Card could print, so the record with the most exact dose carries no per-ounce figure at all, its value row graded 6 on the opacity. Compulsion, read closely, is not a standard of candour. It is a floor with a template, and the records stand above it, on it, and in one case beside an empty price tag, in that order.

The voluntary record, read at the same resolution, is the fullest single document the grooming run has graded, and its fullness is the point. The INKEY List prints its salicylic acid third of 15, doses it at 2%, doses two further components beside it, prints its pH where the buyer can find it, prints its ten minutes, prints its frequency, and leaves both the Fragrance entry and the alcohol off the list entirely. Every column this column has ever counted, the dose column of No. 2, the time column of No. 8, the pH column of No. 15, stands filled on one cosmetic record, filled by choice, at $3.35 an ounce, in the middle of the shelf’s price range. Its one defect is a door: the maker’s United States store listed it Notify Me at the Card’s check, so the shelf’s most complete document ships pill-less, its price standing as printed. The desk notes the symmetry without enjoying it. The record that does everything voluntarily cannot currently be bought at its maker’s own American storefront, and the records that can be bought at theirs print, between them, one voluntary number in eight bottles.

The value column closes the count, and it is the count the prestige end of the shelf will least enjoy. The dosed ounces: the Head & Shoulders at $0.89, the shelf’s cheapest, a drugstore panel record; the Nizoral at $2.41; the Jupiter at $3.29 at its maker, with Target listing the same bottle at $2.00 an ounce, the plurality printed on its card; the winner at $3.35. The undosed ounces: the Kiehl’s at $4.76, the Briogeo at $5.25, the Christophe Robin at $6.48, the dearest on the page. Every dosed ounce is cheaper than every undosed ounce, with no overlap and no exception among the seven records that print an ounce at all. And the Card’s paperwork holds one more figure that sharpens it: the cheapest dosed ounce read for the page belongs to a rested record, the CeraVe Anti-Dandruff Hydrating Shampoo, a pyrithione zinc 1.0% panel at $0.83 an ounce, set aside so the page would not carry two records dosed by the same citizen of the panel. The pattern is not that drugs are cheap, though on this page they are. The pattern is that disclosure and price are sorted by different authorities: the price by the house’s altitude, the number by the bottle’s filing, and a buyer who shops the shelf by price is walking away from the numbers in exact proportion as he spends.

What the compelled number costs

The first cost is a confusion this column is obliged to name because its own method creates it: compliance reads as virtue. A buyer comparing the shelf meets four percentages in one typeface of authority and one percentage in a maker’s ordinary copy, and the natural reading is that five houses are candid and three are coy. The record says otherwise. Four of the five numbers are the same act performed four times, a filing, and the houses performing it include one this desk has charged with a missing charcoal list, a scrub whose copy led with the wrong bead, and a hair oil whose named oil stood behind its system, on three other Cards. The Brickell that prints 1.80% to two decimals is the Brickell of those records, and its panel is not a conversion; it is a category. When compelled disclosure is spent as a character reference, the makers who file drugs collect a reputation for candour they did not earn and the one maker who earned it, voluntarily, at the top of the ranking, is read as merely the fifth candid house on the shelf. The ranking is the correction, which is why this desk prints rows and not vibes: the voluntary document outscores the compelled ones on the honesty row itself, 28 to the best panel’s 26 and 24, because the rows grade what surrounds the number, and what surrounds a compelled number is often an alphabetical shrug.

The second cost is paid by the undosed records’ own claims, which are left standing with nothing to be measured against. The Briogeo’s clinical lines, up to 82% flaking, up to 120% hydration, are percentages, printed large, and they are the only percentages on its record: the house prints numbers for what the product is claimed to do and no number for what the product is. The Christophe Robin’s salt stands first and unmeasured, its claim cashed by a seat, the one proportion evidence a cosmetic prints, as Take No. 17 ruled on the oil shelf; the Kiehl’s counts its amino acids at ten by the house’s count against eleven amino names standing on its own list, all twenty-first or later. A shelf where the law numbers the drugs and nobody numbers the cosmetics teaches its buyers a habit that outlives the shelf: that a percentage is a drug’s furniture, not a buyer’s instrument, and that at the prestige end the correct document is a list with a story in it. Each prestige record that sells at $5 and $6 an ounce with its active unmeasured makes the next voluntary number look less like candour and more like a category error, a drugstore habit on a luxury bottle. The volunteer at the top of this ranking is priced at $3.35 an ounce, and the shelf’s economics will be read, wrongly and predictably, as the reason.

The third cost compounds forward, and it is the cost of a lesson taught to every formulator watching the shelf. The lesson is that the number is never the maker’s problem. File the bottle as a drug and the panel prints the dose, to a template, at no reputational risk, since every competitor’s panel reads the same. File it as a cosmetic and the dose becomes optional, and optional, at the prestige end, means omitted, three times in three houses on one page. No house on this shelf was punished by its category and none was rewarded by its choice except in this desk’s ranking, which is a small jurisdiction. The standing evidence that a voluntary number is commercially survivable stands at the head of the Card anyway, an 86 with three percentages and the shelf’s only pH, outscoring four federal panels on their own shelf. The convention the scalp shelf actually proves is narrower than the industry’s usual defence and harder to hide behind: makers do not omit the dose because buyers cannot use it, or because cosmetics cannot carry it. They omit it where they are allowed to, and print it, to two decimal places, where they are not. The allowance is the whole explanation, and it is printed, by four panels and one volunteer, on the record.

The other side, stated fairly

The case against this Take is a serious one, and it runs in three parts. First: cosmetic law does not define a dose for a cosmetic claim, because a cosmetic makes no dose claim. A salt scrub’s instrument is mechanical, a crystal and a massage, and its proportion is its texture; demanding a percentage of sea salt is a category error the law is right not to make, and a percentage printed without a drug framework behind it invites exactly the cross-class misreading Take No. 15 warned against, a buyer comparing a cosmetic’s 2% against a drug’s 1.80% as if the two figures were the same kind of fact, when one is a filed specification with a monograph behind it and the other is a maker’s arithmetic with nothing behind it at all. Second: the panels’ numbers are labelling, not candour, and grading them in an honesty column confuses compliance with virtue. A maker who prints what the template requires has disclosed nothing he chose to disclose; the honest document on this shelf, by that standard, is the full cosmetic list, and the prestige records publish theirs entire, seats countable, claims printed as claims, which is more voluntary disclosure than any panel’s boilerplate. Third: the volunteer’s completeness is a format, not a standard. The INKEY List’s whole house style is the printed percentage, a brand built on naming actives and dosing them in the product names across its catalogue; its scalp record’s three percentages are its livery, as much marketing as any prestige house’s silence, and a column that crowns the livery has graded a brand strategy, not a shelf’s ethics. The drugstore ounces are cheap because drugstore distribution is cheap, and the prestige ounces are dear because texture and ritual are what prestige sells; the price inversion this Take prints is two retail categories photographed side by side, not a verdict on disclosure.

Each part is true about something, and the record answers each on its own ground. To the category defence: conceded that no percentage is owed by a salt, and this Take asks for none; the Card graded the Robin’s seat, first of 21, as the claim’s cash, exactly as the oil shelf’s rule prescribes, and the record stands at 75, mid-field and respected. What the defence cannot cover is the shelf’s own composition: the undosed three are not all mechanical scrubs. The Kiehl’s seats a chemical active, salicylic acid, sixteenth on its list, the same molecule two other records dose at 1.80% and 2%, and offers no figure for it; the Briogeo sells clinical percentages for its effects and none for its contents. A molecule does not stop being measurable where the filing changes, and a buyer is entitled to notice that the same acid is a specification on two bottles and a garnish on a third, dearer one. As for the misreading risk: it is real, this column printed it, and the answer stands on the winner’s record, which prints its class, its dose, its pH, its minutes and its frequency together, the complete document in which a number cannot be misread because its terms stand beside it. The defence asks the shelf to choose between a bare number and none. The winner prints a third thing, a number with its context, voluntarily, in the cosmetic class, which settles whether it can be done.

To the compliance limb: agreed, and printed in this issue’s own questions before the counter could raise it, that a panel is not a character reference. But the conclusion does not follow. The desk grades the document the buyer is handed, not the motive that produced it, because the buyer spends the document, not the motive. A compelled 1% still tells him what a voluntary silence does not; a compelled 1.80% still lets him compare the Brickell against the volunteer’s 2% and against the Kiehl’s unmeasured sixteenth seat, and that comparison is information whatever its provenance. And the rows are built precisely so that compliance cannot masquerade as candour for long: the compelled records’ honesty rows run 24, 26, 22 and 21, every one below the volunteer’s 28, because the rows grade the whole document, the alphabetical inactives, the unmentioned antiseptics, the missing price, and find the panels exactly as candid as they are. Compliance is graded as compliance, in numbers, on the Card. What this Take adds is only the observation that on this shelf, the floor the law sets is higher than the ceiling the prestige houses choose, and a buyer deserves to be told which of the two he is reading.

To the livery limb, the strongest of the three: conceded that the volunteer’s percentages are its house style, and that a style can be a strategy. But a strategy that consists of printing the dose is the one strategy this column has spent eighteen issues asking the industry to adopt, and it cannot be discounted for being deliberate without discounting every honest record in the run, the one-line oil list and the masque’s printed ceiling included, all of which were also choices made by houses that knew their buyers valued them. The test is not whether the disclosure was strategic. The test is whether the document is complete, and on this shelf one cosmetic document is. To the retail-categories limb: distribution explains some of the spread and the desk prints the doors so the spread can be read with them; it does not explain the ordering inside the prestige group itself, three undosed ounces dearer than every dosed one, nor the rested CeraVe panel at $0.83 an ounce undercutting the ranked drugstore record, nor why the volunteer, a direct-to-consumer cosmetic with no drugstore distribution at all, prices its complete document at $3.35. Price and disclosure are sorted by different authorities on this page, and the authorities are named: the house sets the price, and the law, or one house’s livery, sets the number. The buyer who knows which authority printed what he is reading is the buyer this column exists to make.

The picks, as published on the Card

The discipline for using any of them is the Card’s, unchanged: read the panel before the prestige, ask who required every number you are shown, and treat an unmeasured active at a prestige ounce as a claim, not a dose. The standing offer of this column applies to the shelf in its own terms: the first prestige house to print its cosmetic’s dose voluntarily, with its class and its contact beside it, will be named here, at the top of a re-argued column, the same day its record can be read. The proof that it can be done already stands twice on this record: at the head of the ranking, where a cosmetic printed three percentages by choice and outscored four federal panels, and inside the sent-home house’s own line, where the dose is printed on the bottle the law files as a drug. The documents exist in every maker’s files. On this shelf they are simply filed, and the filing goes first.

What this page does not claim

On the evidence. This page scores nothing and tests nothing. Every score, row, price, position and percentage is Verdict Card No. 100’s, reproduced exactly as that Card published it, and the Card’s own evidence discipline stands behind it: the desk grades published ingredient lists in the maker’s order and federal panels as filed, makers’ claims graded as claims, reported wear labelled as reported wherever it appears, and prices per ounce with the arithmetic printed, and asserts nothing about what any active does to any scalp. The counts this Take adds, the sorting of the five dosed records into four compelled and one voluntary, and the price ordering of dosed against undosed ounces, are counts of the Card’s printed record and are printed as counts so they can be recounted. Where the Card’s record rests on a document a maker revises, the graded version is the one named: the Briogeo on its fuller 29-line rendering, the Christophe Robin on its maker’s list against the retailer’s 23-line rendering, the Nizoral on its current label with its inactives alphabetical.

On the brief’s premises, checked against the record. This issue was briefed on the Card’s dose census, and the census survived the record entire, which the honesty section prints because the column’s habit is to print its corrections and its confirmations in the same place. Survived: a dosed active on five of eight; four of the five dosed under federal Drug Facts panels, ketoconazole 1%, selenium sulfide 1%, zinc pyrithione 1.0% and salicylic acid 1.80%; exactly one cosmetic record dosing voluntarily, The INKEY List at 2%, and that record winning the Card; the three undosed records standing as the prestige cosmetics; the sent-home scrub’s named ingredient standing fourteenth on its own list; and the prices running against the disclosure, the dosed drugstore ounce the cheapest on the page and the undosed prestige ounce the dearest. Two precisions the record adds, printed rather than absorbed. First, the cheapest dosed ounce read for the page is not on the ranking: the rested CeraVe panel record stands at $0.83 an ounce in the Card’s paperwork, set aside to avoid a second pyrithione zinc record, so the cheapest dosed ounce among the ranked eight is the Head & Shoulders’ $0.89, and this issue prints the distinction rather than rounding the rested figure into the ranking’s claim. Second, the undosed three are not undocumented: their lists are complete, their frequencies printed, and one prints the shelf’s only use dose for a physical exfoliant; the blank this issue charges is the percentage alone, stated exactly, and the winner’s margin over the best panel is four honesty points, not a rout. One count is stated exactly: of the eight records, five print a dose, and of those five, one chose to.

On what scalp treatments do. Nothing on this page says any active clears, calms or revives any scalp, and nothing says any percentage is the right strength for any reader; the clinical figures quoted from the sent-home record, up to 82% flaking and up to 120% hydration, are quoted as a maker’s claims graded as claims on its Card, not as findings of this desk. Efficacy is graded nowhere here. What is graded is the document the buyer is handed: whether a dose is printed, who required it, where the named ingredient stands, and what the ounce costs against what it discloses. The desk opened no bottle and filed no panel for this issue. The argument is about what is printed for a reader to read before the purchase, and on eight records what is printed is a number wherever a statute asks for one, a number in one place where it does not, and a story everywhere else.

On the photographs, and on the record moving. There are no photographs of ranked products on this page because there are none to print: the photo bank holds no scalp scrub or treatment product photography, and no grooming product or bathroom-shelf photography of any kind, a gap the ranking names on its own page, and the hero and figure here are frames of the subject itself, the scalp ranking’s own hero and a portrait at examining distance, captioned for what they show, which is a wearer, not a product. The record itself moves underneath this argument: the winner’s United States door stood at Notify Me at the Card’s check, owed to the November pass with the Kiehl’s scrub’s exact door and the Brickell’s standalone price; the Briogeo circulates in two list renderings, the shorter omitting the Fragrance line the fuller prints at twenty-seventh; the Jupiter’s door plurality, $28.00 at its maker against $16.99 at Target for the same bottle, stands printed on its card; and the Head & Shoulders record is one panel under a range name that covers at least three, graded on the Dry Scalp Rescue record its Target door sells. The scores and the rule stand as published until a cited record changes; when one does, the Card moves first and this Take is re-argued from it, in the open.

Questions, answered from the record

Next

The record this issue argues from stands in full at the scalp ranking, Verdict Card No. 100, where every list and panel quoted here is printed in its maker’s order and every bottle carries its own card. The hair shelf around it continues at the hair mask Card, No. 99, where the named repair technology’s standing on its own list was the count, the hair oil Card, No. 98, where the oil stood fifth behind its system, the shampoo Card, No. 70, and the conditioner Card, No. 71, where the pair was graded as strangers. The kinship runs three ways: Take No. 7 and Take No. 15 are the parent arguments, the number is not the dose and the rinse is not the dose, since there a printed strength still owed its minutes and its class before it could be spent, a percentage being a strength and a dose only the strength multiplied by its contact, while here the strength itself is sorted before the minutes are asked, printed where a statute files the bottle as a drug and withheld where the filing lets it be withheld, so that the dose column and the contact column turn out to be governed by the same authority, the category, and not by the maker’s candour at all; Take No. 2 governs the voluntary half, the number nobody prints, since there the dose stood printed on a compelled minority of one shelf and the voluntary column stood empty by custom, while here the custom is populated by compulsion, four panels printing the number the custom withholds, and the voluntary column holds exactly one citizen in eight, and that citizen wins the Card; and Take No. 17 is the nearest sibling, the oil stands fifth, since there one house sold the honest bottle and the story bottle in a single catalogue at two price tags, while here one house prints the dose and withholds it in a single line at two filings, the number standing where the law asks and nowhere the law does not, so the catalogue’s two documents differ not in the house’s capability but in its obligations. Next, The Grooming Take No. 19, The Technology Is Not Dosed: the hair mask shelf sells a technology it doses nowhere, where K18 wins at 81 on the fullest partial record the grooming desk has yet seated, a peptide at ninth, a pH and a four-minute clock printed, and the dose beyond that printed by volume alone, and the sent-home bottle promises six months of damage repaired in one use with no bonding molecule on its fifteen-line list, this Take’s nearest relative once removed, since there the dose stood on the label because the law compels it on a drug, and here every bottle is a cosmetic and no law compels it, so the compelled count and the voluntary count are the same count, zero. The franchise so far: No. 1, grooming is sold by the step and works by the habit; No. 2, the number nobody prints; No. 3, one tube, two honesties; No. 4, the pair graded as one record; No. 5, the name is not the number; No. 6, the name is not in the list; No. 7, the number is not the dose; No. 8, the minute is the dose; No. 9, the ritual is not an ingredient; No. 10, the hold is an adjective; No. 11, the name is not an ingredient; No. 12, the burn is not the proof; No. 13, the copy is not the list; No. 14, the number is in another country; No. 15, the rinse is not the dose; No. 16, the step is not a species; No. 17, the oil stands fifth; No. 19, the technology is not dosed. How every score on this site is built is set out in the methodology. The Takes continue by number; the next one starts, as this one did, from a record that already exists or a blank that is printed as one.